Cardinal Health, Inc.

Regeneron Pharmaceuticals: A Deep Dive into the Leadership and Commercial Infrastructure Behind a Biopharma Powerhouse

- Regeneron Pharmaceuticals, co-founded in 1988 by Dr. Leonard S. Schleifer, has grown into a global biopharma leader with a diverse portfolio spanning ophthalmology, immunology, oncology, and rare diseases. - The company's commercial model relies on major pharmaceutical wholesalers—McKesson, AmerisourceBergen, and Cardinal Health—as well as direct government contracts, notably with the U.S. Department of Health and Human Services for REGEN-COV. - Key products include EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for skin cancers, Praluent for cardiovascular conditions, and Kevzara for rheumatoid arthritis. - The executive leadership team, including CSO Dr. George D. Yancopoulos and CFO Christopher Fenimore, combines deep scientific expertise with strategic financial oversight to drive the company's R&D and commercial operations.